BACKGROUND: Artemisinin-based combination therapies, including artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP), are recommended to treat uncomplicated falciparum malaria. Sensitivities to components of AL and DP are impacted by polymorphisms in pfmdr1 and pfcrt. We monitored changes in prevalences of polymorphisms in Tororo, Uganda, from 2008 to 2012. METHODS: Polymorphic loci in pfmdr1 and pfcrt were characterized in samples from 312 children randomized to AL or DP for each episode of uncomplicated malaria (50 samples per arm for each 3-month interval) utilizing a fluorescent microsphere assay. Treatment outcomes and impacts of prior therapies were also characterized. RESULTS: Prevalence increased significantly over time for pfmdr1 N86 (AL: odds ratio [OR], 2.08 [95% confidence interval {CI}, 1.83-2.38]; DP: 1.41 [95% CI, 1.25-1.57]), pfmdr1 D1246 (AL: 1.46 [95% CI, 1.29-1.64]; DP: 1.36 [95% CI, 1.23-1.50]), and pfcrt K76 (AL: 3.37 [95% CI, 1.85-6.16]; DP: 5.84 [95% CI, 1.94-17.53], and decreased for pfmdr1 Y184 (AL: 0.78 [95% CI, .70-.86]; DP: 0.84 [95% CI, .76-1.50]); changes were consistently greater in the AL arm. Recent AL treatment selected for pfmdr1 N86, D1246, and 184F in subsequent episodes; DP selected for the opposite alleles. CONCLUSIONS: Genotypes with decreased sensitivity to AL components increased over time. This increase was greater in children receiving AL, suggesting that the choice of treatment regimen can profoundly influence parasite genetics and drug sensitivity. CLINICAL TRIALS REGISTRATION: NCT00527800.
BACKGROUND:Artemisinin-based combination therapies, including artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP), are recommended to treat uncomplicated falciparum malaria. Sensitivities to components of AL and DP are impacted by polymorphisms in pfmdr1 and pfcrt. We monitored changes in prevalences of polymorphisms in Tororo, Uganda, from 2008 to 2012. METHODS: Polymorphic loci in pfmdr1 and pfcrt were characterized in samples from 312 children randomized to AL or DP for each episode of uncomplicated malaria (50 samples per arm for each 3-month interval) utilizing a fluorescent microsphere assay. Treatment outcomes and impacts of prior therapies were also characterized. RESULTS: Prevalence increased significantly over time for pfmdr1 N86 (AL: odds ratio [OR], 2.08 [95% confidence interval {CI}, 1.83-2.38]; DP: 1.41 [95% CI, 1.25-1.57]), pfmdr1 D1246 (AL: 1.46 [95% CI, 1.29-1.64]; DP: 1.36 [95% CI, 1.23-1.50]), and pfcrt K76 (AL: 3.37 [95% CI, 1.85-6.16]; DP: 5.84 [95% CI, 1.94-17.53], and decreased for pfmdr1 Y184 (AL: 0.78 [95% CI, .70-.86]; DP: 0.84 [95% CI, .76-1.50]); changes were consistently greater in the AL arm. Recent AL treatment selected for pfmdr1 N86, D1246, and 184F in subsequent episodes; DP selected for the opposite alleles. CONCLUSIONS: Genotypes with decreased sensitivity to AL components increased over time. This increase was greater in children receiving AL, suggesting that the choice of treatment regimen can profoundly influence parasite genetics and drug sensitivity. CLINICAL TRIALS REGISTRATION: NCT00527800.
Authors: Samuel L Nsobya; Christian Dokomajilar; Moses Joloba; Grant Dorsey; Philip J Rosenthal Journal: Antimicrob Agents Chemother Date: 2007-06-11 Impact factor: 5.191
Authors: Maria Isabel Veiga; Pedro Eduardo Ferreira; Louise Jörnhagen; Maja Malmberg; Aminatou Kone; Berit Aydin Schmidt; Max Petzold; Anders Björkman; Francois Nosten; Jose Pedro Gil Journal: PLoS One Date: 2011-05-25 Impact factor: 3.240
Authors: Leah Mwai; Abdi Diriye; Victor Masseno; Steven Muriithi; Theresa Feltwell; Jennifer Musyoki; Jacob Lemieux; Avi Feller; Gunnar R Mair; Kevin Marsh; Chris Newbold; Alexis Nzila; Céline K Carret Journal: PLoS One Date: 2012-02-27 Impact factor: 3.240
Authors: Jennifer L Guler; Daniel L Freeman; Vida Ahyong; Rapatbhorn Patrapuvich; John White; Ramesh Gujjar; Margaret A Phillips; Joseph DeRisi; Pradipsinh K Rathod Journal: PLoS Pathog Date: 2013-05-23 Impact factor: 6.823
Authors: Anne Liljander; Lisa Wiklund; Nicole Falk; Margaret Kweku; Andreas Mårtensson; Ingrid Felger; Anna Färnert Journal: Malar J Date: 2009-04-23 Impact factor: 2.979
Authors: Erika Wallender; Nan Zhang; Melissa Conrad; Abel Kakuru; Mary Muhindo; Patrick Tumwebaze; Richard Kajubi; Daniel Mota; Jennifer Legac; Prasanna Jagannathan; Diane Havlir; Moses Kamya; Grant Dorsey; Francesca Aweeka; Philip J Rosenthal; Rada M Savic Journal: Antimicrob Agents Chemother Date: 2019-01-29 Impact factor: 5.191
Authors: Patrick Tumwebaze; Stephen Tukwasibwe; Aimee Taylor; Melissa Conrad; Emmanuel Ruhamyankaka; Victor Asua; Andrew Walakira; Joaniter Nankabirwa; Adoke Yeka; Sarah G Staedke; Bryan Greenhouse; Samuel L Nsobya; Moses R Kamya; Grant Dorsey; Philip J Rosenthal Journal: J Infect Dis Date: 2017-02-15 Impact factor: 5.226
Authors: Roland A Cooper; Melissa D Conrad; Quentin D Watson; Stephanie J Huezo; Harriet Ninsiima; Patrick Tumwebaze; Samuel L Nsobya; Philip J Rosenthal Journal: Antimicrob Agents Chemother Date: 2015-06-01 Impact factor: 5.191
Authors: Joaniter I Nankabirwa; Melissa D Conrad; Jennifer Legac; Stephen Tukwasibwe; Patrick Tumwebaze; Bonnie Wandera; Simon J Brooker; Sarah G Staedke; Moses R Kamya; Sam L Nsobya; Grant Dorsey; Philip J Rosenthal Journal: Antimicrob Agents Chemother Date: 2016-09-23 Impact factor: 5.191
Authors: Patrick Tumwebaze; Melissa D Conrad; Andrew Walakira; Norbert LeClair; Oswald Byaruhanga; Christine Nakazibwe; Benjamin Kozak; Jessica Bloome; Jaffer Okiring; Abel Kakuru; Victor Bigira; James Kapisi; Jennifer Legac; Jiri Gut; Roland A Cooper; Moses R Kamya; Diane V Havlir; Grant Dorsey; Bryan Greenhouse; Samuel L Nsobya; Philip J Rosenthal Journal: Antimicrob Agents Chemother Date: 2015-03-09 Impact factor: 5.191